20mins delayed


1 Year Return

System message

BIG CHANGES! Try the new Market Index

For the best experience, create a free account.

INVEX Therapeutics Ltd Chart

Share price
Market Cap $40.83 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

IXC Statistics

21 January

1,420 / 2,257

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$40.83 million

Market Cap

Share Issue

54.08 million

All Ords (%)


Short Sold


Current Fundamentals

21 January


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.

INVEX Therapeutics Ltd Logo

Corporate Details

Head Office: Subiaco
Managing Director: -
GICS Sub-Industry: Pharmaceuticals
Date Listed: 5 Jul 2019
Registry: Automic
Similar Companies: SPL / MYX / AFP / EOF / MVP

Upcoming Calendar

25 Feb 2021 Report (Interim)
27 Aug 2021 Report (Prelim)
27 Aug 2021 Report (Annual)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Announcements provided by

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

IXC is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data

Name Title Since Bio
Mr David McAuliffe Non-Executive Director Mar 2019
Ms Narelle Warren Chief Financial Officer, Company Secretary Mar 2019
Dr Jason Loveridge Non-Executive Chairman, Non-Executive Director Mar 2019
Dr Thomas (Tom) Duthy Executive Director Oct 2020
Dr Alexandra J Sinclair Chief Scientific Officer, Executive Director Jun 2019

Director Transactions

About the Data

IXC directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
22/11/19 David McAuliffe Issued 200,000 $0.710 $142,000 Issue of options.
22/11/19 Narelle Warren Issued 400,000 $0.710 $284,000 Issue of options.
22/11/19 Jason Loveridge Issued 800,000 $0.710 $568,000 Issue of options.
22/11/19 Alexandra Sinclair Issued 800,000 $0.710 $568,000 Issue of options.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 274 416 184 357 86 1,317

Top 20 Shareholders

About the Data

Name Shares Capital
Tattarang Pty Ltd 13,841,670 23.45%
Tisia Nominees Pty Ltd 5,000,000 8.47%
Jk Nominees Pty Ltd 2,820,896 4.78%
Anthony Grist 1,690,000 2.86%
Dr Jason Loveridge 1,561,729 2.65%
Mr David Jerimiah Mcauliffe 1,150,000 1.95%
HSBC Custody Nominees (Australia) Limited 1,041,667 1.76%
Alexandra Jean Sinclair 933,334 1.58%
Ms Kathryn Mary Salkilld 650,000 1.10%
Citicorp Nominees Pty Ltd 600,000 1.02%
The University Of Birmingham 590,000 1.00%
Sunset Capital Management Pty Ltd 500,000 0.85%
Bannaby Investments Pty Limited 500,000 0.85%
Bnp Paribas Nominees Pty Ltd Hub 24 Custodial Serv Ltd Drp 482,500 0.82%
Cityscape Asset Pty Ltd 455,000 0.77%
Hsbc Custody Nominees (Australia) Limited-Gsi Eda 430,000 0.73%
Sandhurst Trustees Ltd 425,584 0.72%
Hsbc Custody Nominees (Australia) Limited-Gsi Eda I 400,000 0.68%
J P Morgan Nominees (Australia Limited 400,000 0.68%
Cs Third Nominees Pty Limited 375,000 0.64%
All other shareholders 42.64 %

The Top 20 Shareholders of IXC hold 57.36% of shares on issue.

IXC Share Price History

Date Close Change % Change Open High Low Volume Turnover

IXC Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade
2020 $1.30 30 June

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Biopharmaceuticals.

Incorporated: --

Level 1, 38 Rowland St
Subiaco WA 6008

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.